Earlier this week, Mark Cuban weighed in on one of the year’s louder debates in medicine with a post on X: “No chance radiologists get replaced. A model is outdated the minute it is released. Model usage costs money. A lot more than a radiologist. Medicine is a business. Putting together AI with domain knowledge is complex.” The post stands out because it argues against AI replacing a specialty on cost and liability grounds rather than on capability grounds.
Cuban’s logic is worth pulling apart. Foundation models drift the moment they ship. Inference at clinical scale carries a real per-query bill. And, in his framing, medicine is a business in which the combination of AI and domain expertise is genuinely hard to assemble.
Where Cuban Thinks the Automation Actually Lands
Earlier the same morning, Cuban drew the other side of the line in a separate post: “AI will replace most doctors [sic] tasks! Because most of their tasks are [expletive removed] administrivia introduced by the huge HC conglomerates that serve no purpose.” Read together, the two posts describe one position. Clinical judgment under liability and cost pressure stays. Administrative paperwork, in his view, does not have to.
The administrative layer Cuban is describing is concentrated in a handful of vertically integrated, publicly listed companies, most visibly in the pharmacy benefit manager (PBM) business. A PBM sits between drug manufacturers, insurers, pharmacies, and patients, negotiating prices, setting formularies, and processing claims. Critics call PBMs middlemen; the companies argue they hold down drug costs.
CVS Health (NYSE:CVS | CVS Price Prediction) owns Caremark. In Q2 2026, Health Services revenue reached nearly $52 billion, and CEO David Joyner told investors CVS had launched an AI-enabled claims-assist manager that will reduce processing time by over 20% and accelerate payment for providers on hundreds of millions of claims every year. Aetna executive Steve Nelson said Aetna 1 advocates who used to spend 90 minutes preparing a case now take only two minutes. Shares are up 21% year to date.
Cigna (NYSE:CI) owns Express Scripts inside Evernorth. Q2 2026 Evernorth revenue was $61.5 billion, though pharmacy benefit services pre-tax adjusted earnings came in at $609 million, down year over year as Cigna invests in its rebate-free Signature model. CEO Brian Evanko said Cigna’s Pharmacy Forward program uses AI to cut time to therapy in half on average and reduce clinician documentation time by up to 50%. Shares are roughly flat year to date.
And of course, UnitedHealth Group (NYSE:UNH) owns Optum Rx. UnitedHealthcare committed to eliminating 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care by year-end, and targets processing 80% of prior authorizations in real time by the end of 2027. Optum’s digital prior auth product reports 96% first-pass approval. Q2 revenue was $112 billion. Shares are up 18% year to date.
Consider the Source, Then Consider the Argument
Cuban co-founded Mark Cuban Cost Plus Drug Company, which was built to bypass the PBM layer with transparent pricing, so he of course has a viewpoint on this.
And also – the three conglomerates are already deploying AI against the exact administrative work Cuban says should go. Whether that compresses their margins or expands them is the open question for investors holding these names. Cuban’s framing inverts the usual AI-disruption story: the specialists may keep their jobs; the administrative layer that pays for a lot of enterprise value at CVS, Cigna, and UnitedHealth may not keep all of its scope.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks